[{"orgOrder":0,"company":"Biosolution","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Costal Chondrocyte","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosolution","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Biosolution \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biosolution \/ Undisclosed"},{"orgOrder":0,"company":"Biosolution","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Costal Chondrocyte","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosolution","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Biosolution \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biosolution \/ Undisclosed"},{"orgOrder":0,"company":"Biosolution","sponsor":"Mundipharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"Chondrocytes","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Biosolution","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosolution \/ Biosolution","highestDevelopmentStatusID":"1","companyTruncated":"Biosolution \/ Biosolution"}]

Find Clinical Drug Pipeline Developments & Deals by Biosolution

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : CartiLife (Autologous Costal Chondrocyte) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cartilage Diseases.

                          Product Name : CartiLife

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          September 21, 2021

                          Lead Product(s) : Autologous Costal Chondrocyte

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : CartiLife (Autologous Costal Chondrocyte) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cartilage Diseases.

                          Product Name : CartiLife

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          February 09, 2021

                          Lead Product(s) : Autologous Costal Chondrocyte

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Under the agreement, Mundipharma obtains the rights to market and distribute CartiLife® in South Korea.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          January 06, 2020

                          Lead Product(s) : Chondrocytes

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Undisclosed

                          Recipient : Mundipharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank